| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T25 |
0-190 |
Sentence |
denotes |
Although much about SARS-CoV-2 biology can be inferred based on similarity to SARS-CoV, SARS-CoV-2 is a novel coronavirus with unique properties that contribute to its pandemic-scale spread. |
| T26 |
191-413 |
Sentence |
denotes |
Unlike SARS-CoV, SARS-CoV-2 infection is commonly asymptomatic, particularly in the younger population (Guan et al., 2020), and contagious prior to symptom onset (Rothe et al., 2020; Peiris et al., 2003; Bai et al., 2020). |
| T27 |
414-623 |
Sentence |
denotes |
These characteristics contribute to the difficulty of containing SARS-CoV-2 spread through public health strategies and amplify the need to develop vaccines and therapies to protect against and treat COVID-19. |
| T28 |
624-719 |
Sentence |
denotes |
Clinical management of COVID-19 is largely limited to infection prevention and supportive care. |
| T29 |
720-908 |
Sentence |
denotes |
So far, remdesivir, a broad-spectrum antiviral agent, is the only medication approved for emergency use to treat COVID-19 by the US Food and Drug Administration (FDA) (Grein et al., 2020). |
| T30 |
909-1184 |
Sentence |
denotes |
Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient setting, to effectively combat the COVID-19 pandemic. |
